Imunon Stock Earnings Reports

IMUNON reported strong clinical momentum for IMNN-001 following completion of the Phase II OVATION 2 study, which showed a clinically meaningful median overall survival (OS) benefit (~14.7 months). The pivotal Phase III OVATION 3 is underway (500 patients) and management remains on track to randomize ~80 patients by Q1 2027 with full enrollment targeted in Q1 2029. The trial is open-label (unblinded to sites/patients) with OS as the primary endpoint and two planned interim analyses that could allow early stopping for efficacy. Management emphasized favorable safety/tolerability, encouraging investigator engagement driving faster-than-forecast enrollment, and supportive translational data to be presented at upcoming scientific forums and an R&D Day in Q3 2026. Financially, Q1 2026 R&D was $2.3M, G&A $2.0M, and net cash used in operations $4.0M; the company is pursuing a disciplined bridge financing strategy aimed at extending runway while minimizing dilution (including potential preferred-share structures) and expects near-term quarterly spend in the $4.5–$5.0M range as OVATION 3 enrollment ramps. Management is focused on securing financing that aligns with long-term investor/shareholder interests and preparing for a potential BLA pathway grounded on OS readout.